Their forecasts range from $17.00 to $34.50. Pre-Market earnings guidance on Monday, May, 11th. High institutional ownership can be a signal of strong market trust in this company.Earnings for Mylan are expected to grow by 2.54% in the coming year, from $4.33 to $4.44 per share.The P/E ratio of Mylan is 134.26, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.87.The P/E ratio of Mylan is 134.26, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.70.Mylan has a PEG Ratio of 1.81.
The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.According to analysts' consensus price target of $22.94, Mylan has a potential upside of 42.4% from its current price of $16.11.Mylan has only been the subject of 2 research reports in the past 90 days.Mylan has received 54.54% “outperform” votes from our community.Mylan does not have a long track record of dividend growth.In the past three months, Mylan insiders have not sold or bought any company stock.Only 0.59% of the stock of Mylan is held by insiders.85.58% of the stock of Mylan is held by institutions. Mylan NV (NASDAQ:MYL) posted its earnings results on Tuesday, May, 7th. Learn about financial terms, types of investments, trading strategies and more.MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. PEG Ratios above 1 indicate that a company could be overvalued.Mylan has a P/B Ratio of 0.70. On average, they expect Mylan's stock price to reach $22.94 in the next year. This suggests a possible upside of 42.4% from the stock's current price. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals.
The company had revenue of $2.62 billion for the quarter, compared to analyst estimates of $2.65 billion. The firm's revenue was up 5.0% compared to the same quarter last year.
P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.Mylan's management team includes the following people:
Export data to Excel for your own analysis.
Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; TB Alliance; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Mylan earned a news impact score of 0.2 on InfoTrie's scale. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. Please log in to your account or sign up in order to add this asset to your watchlist. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.74 billion.10 brokerages have issued twelve-month price targets for Mylan's stock.
The business earned $2.50 billion during the quarter, compared to analyst estimates of $2.70 billion. Mylan will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Since then, MYL stock has increased by 11.3% and is now trading at $16.11. Company insiders that own Mylan stock include Goulds Bruce, Melina E Higgins, Paul Campbell, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. Top institutional investors include Pzena Investment Management LLC (3.24%), Retirement Systems of Alabama (0.24%), First Trust Advisors LP (0.22%), SG Americas Securities LLC (0.15%), New York State Teachers Retirement System (0.14%) and State of Alaska Department of Revenue (0.08%). Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Mylan trades on the NASDAQ under the ticker symbol "MYL. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury, and Sjoerd S Vollebregt. 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." The company can be reached via phone at 724-514-1800 or via email at Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Mylan is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. The company provided EPS guidance of for the period.